BioNexus Gene Lab Corp.
BGLC | NASDAQ
$1.45
-$0.05 (-3.33%)
Sep 22, 2026, 10:58 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 7.42M | 9.51M | 9.77M | 10.93M | 13.36M | 11.39M |
Cost of Revenue | 6.34M | 8.22M | 8.44M | 9.67M | 11.17M | 9.67M |
Gross Profit | 1.09M | 1.29M | 1.33M | 1.26M | 2.19M | 1.72M |
Operating Income | -3.16M | -1.57M | -2.59M | -291.18K | 1.06M | 1.27M |
Interest Income | 83.89K | 147.64K | n/a | n/a | n/a | n/a |
Pretax Income | -2.98M | -1.59M | -2.61M | -303.66K | 1.04M | 1.26M |
Net Income | -2.98M | -1.6M | -2.63M | -355.97K | 751.57K | 1.09M |
Selling & General & Admin | 4.07M | 4M | 3.04M | 1.73M | 1.2M | 1.33M |
Research & Development | 50.67K | 47.51K | 54.98K | n/a | n/a | n/a |
Other Expenses | 126.44K | -1.19M | 828.39K | -179.28K | -66.49K | -886.94K |
Operating Expenses | 4.24M | 2.86M | 3.92M | 1.55M | 1.14M | 446K |
Interest Expense | 19.54K | 21.15K | 13.93K | 12.48K | 12.97K | 11.31K |
Selling & Marketing Expenses | 1.74M | 2.03M | 596.86K | n/a | n/a | n/a |
Cost & Expenses | 10.58M | 11.08M | 12.36M | 11.22M | 12.31M | 10.12M |
Income Tax Expense | n/a | 3.49K | 21.53K | 52.31K | 291.28K | 168.41K |
Shares Outstanding (Basic) | 1.86M | 1.78M | 1.72M | 1.44M | 1.43M | 857.65K |
Shares Outstanding (Diluted) | 1.86M | 1.78M | 1.72M | 1.44M | 1.43M | 857.65K |
EPS (Basic) | -1.61 | -0.90 | -1.53 | -0.25 | 0.53 | 1.28 |
EPS (Diluted) | -1.61 | -0.90 | -1.53 | -0.25 | 0.53 | 1.28 |
EBITDA | -2.8M | -1.42M | -2.49M | -185.76K | 1.16M | 1.38M |
EBIT | -2.97M | -1.57M | -2.59M | -291.18K | 1.06M | 1.27M |
Depreciation & Amortization | 168.31K | 153.14K | 108.42K | 105.42K | 108.22K | 101.6K |
Add to Watchlist
Select watchlists to add or remove BGLC